Five Prime Therapeutics, Inc.
FPRX
FPRX was delisted on the 15th of April, 2021.
113 hedge funds and large institutions have $424M invested in Five Prime Therapeutics, Inc. in 2019 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 39 increasing their positions, 30 reducing their positions, and 18 closing their positions.
48% more capital invested
Capital invested by funds: $287M → $424M (+$137M)
30% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 30
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
3% less funds holding
Funds holding: 116 → 113 (-3)
17% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 18
35% less call options, than puts
Call options by funds: $1.35M | Put options by funds: $2.09M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$7.42M |
| 2 |
AC
Armistice Capital
New York
|
+$3.42M |
| 3 |
BI
BVF Inc
San Francisco,
California
|
+$3.23M |
| 4 |
DekaBank Deutsche Girozentrale
Frankfurt,
Germany
|
+$3.11M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
+$2.85M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$3.04M |
| 2 |
SI
Sofinnova Investments
Menlo Park,
California
|
-$2.93M |
| 3 |
BlackRock
New York
|
-$2.52M |
| 4 |
Millennium Management
New York
|
-$1.84M |
| 5 |
AllianceBernstein
Nashville,
Tennessee
|
-$1.78M |
FPRX Hedge Fund Activity: Q1 2019 in Review
113 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Five Prime Therapeutics, Inc. (FPRX) for Q1 2019, worth a combined $424M — up 48% from $287M a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of FPRX and 15 opened new positions — a net loss of 3 holders — while 30 trimmed existing stakes and 39 added.
The largest buyer was Vanguard Group, adding an estimated $7.42M. The largest seller was EcoR1 Capital, exiting entirely with an estimated $3.04M sold.
- 113 institutional investors held Five Prime Therapeutics, Inc. (FPRX) as of Q1 2019, down from 116 in Q4 2018.
- Funds reported $424M of Five Prime Therapeutics, Inc. stock for Q1 2019, up 48% quarter-over-quarter.
- 15 funds opened new Five Prime Therapeutics, Inc. positions in Q1 2019 and 18 closed out, a net change of -3 holders.
- The largest Five Prime Therapeutics, Inc. buyer in Q1 2019 was Vanguard Group, an estimated $7.42M added.
- The largest Five Prime Therapeutics, Inc. seller in Q1 2019 was EcoR1 Capital, an estimated $3.04M sold.
Based on aggregated 13F filings for Q1 2019.